Contacts:

Lorus Therapeutics Inc.

Bruce Rowlands

Senior Vice President

(416) 798-1200 ext. 338

 

browlands@lorusthera.com

 

Media Contact:

Eliza Walsh / Amy Banek

Mansfield Communications

(416) 599-0024 / (212) 370-5045

eliza@mcipr.com

US Investor Relations

Tim Clemensen

Rubenstein Investor Relations

(212) 843-9337

tim@rir1.com


LORUS THERAPEUTICS PRESENTS AT ASIA’S LARGEST BIOTECHNOLOGY CONFERENCE


–Lorus to review progress of its extensive oncology pipeline–


TSX:               LOR

AMEX:          LRP

 

TORONTO, CANADA, September 28, 2004 – Lorus Therapeutics Inc. (“Lorus”) announced today that the company’s chief operating officer, Dr. Aiping Young, and director of business development, Germaine Gross, will attend the BioJapan conference in Tokyo, Japan.  Dr. Young will present a comprehensive review of Lorus’ oncology pipeline to the conference on September 30th.


BioJapan is Asia’s largest biotechnology-related conference.  The conference will include presentations from biotechnology representatives from over seven different countries.  Participants will have the opportunity to investigate potential partnership opportunities, explore Japan's biotech clusters and meet with executives from other biotech companies looking to develop new international relationships.


About Lorus


Lorus is a biopharmaceutical company focused on the research and development of cancer therapies.  Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer.  Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs.  Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners.  Lorus currently has three products in human clinical trials with a pipeline of eight clinical trials in phase II clinical trial programs and one phase III registration clinical trial.  Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.  Virulizin(R) is a registered trademark of Lorus Therapeutics Inc.


Forward Looking Statements


Except for historical information, this press release contains forward-looking statements, which reflect the Company’